Simon Sturge - 05 Apr 2022 Form 3 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Simon Sturge
Issuer symbol
MLTX
Transactions as of
05 Apr 2022
Net transactions value
$0
Form type
3
Filing time
15 Apr 2022, 16:06:53 UTC
Next filing
05 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MLTX Class C ordinary shares, par value $0.0001 per share 342,980 05 Apr 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLTX Common shares, par value CHF 0.10 per share, of MoonLake AG 05 Apr 2022 Class A ordinary shares, par value $0.0001 per share 10,196 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Beginning on October 5, 2022, which is the expiration of the lock-up period set forth in the Restated and Amended Shareholders' Agreement, dated April 5, 2022, by and among the Issuer, the holder and the shareholders of MoonLake Immunotherapeutics AG ("MoonLake AG") signatory thereto, the common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares of the Issuer at a rate of 1 common share for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

Remarks:

Exhibit 24 - Power of Attorney